- Home
- ATCH vs OTLK Comparison
ATCH vs OTLK Comparison
Compare ATCH & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- OTLK
- Stock Information
- Founded
- ATCH 2022
- OTLK 2010
- Country
- ATCH United States
- OTLK United States
- Employees
- ATCH N/A
- OTLK N/A
- Industry
- ATCH
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATCH
- OTLK Health Care
- Exchange
- ATCH Nasdaq
- OTLK Nasdaq
- Market Cap
- ATCH 39.9M
- OTLK 42.8M
- IPO Year
- ATCH N/A
- OTLK 2016
- Fundamental
- Price
- ATCH $0.30
- OTLK $1.64
- Analyst Decision
- ATCH
- OTLK Buy
- Analyst Count
- ATCH 0
- OTLK 5
- Target Price
- ATCH N/A
- OTLK $5.25
- AVG Volume (30 Days)
- ATCH 6.9M
- OTLK 4.7M
- Earning Date
- ATCH 11-14-2025
- OTLK 12-26-2025
- Dividend Yield
- ATCH N/A
- OTLK N/A
- EPS Growth
- ATCH N/A
- OTLK N/A
- EPS
- ATCH N/A
- OTLK N/A
- Revenue
- ATCH $12,303,120.00
- OTLK $1,505,322.00
- Revenue This Year
- ATCH N/A
- OTLK N/A
- Revenue Next Year
- ATCH N/A
- OTLK $342.80
- P/E Ratio
- ATCH N/A
- OTLK N/A
- Revenue Growth
- ATCH 80.78
- OTLK N/A
- 52 Week Low
- ATCH $0.14
- OTLK $0.79
- 52 Week High
- ATCH $16.14
- OTLK $5.18
- Technical
- Relative Strength Index (RSI)
- ATCH 44.20
- OTLK 55.23
- Support Level
- ATCH $0.25
- OTLK $1.76
- Resistance Level
- ATCH $0.30
- OTLK $2.02
- Average True Range (ATR)
- ATCH 0.03
- OTLK 0.20
- MACD
- ATCH 0.00
- OTLK 0.03
- Stochastic Oscillator
- ATCH 46.41
- OTLK 51.56
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.